AUROBINDO PHARMA | LUPIN | AUROBINDO PHARMA/ LUPIN |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 13.8 | -14.6 | - | View Chart |
P/BV | x | 1.4 | 2.6 | 52.0% | View Chart |
Dividend Yield | % | 1.6 | 0.6 | 272.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-22 |
LUPIN Mar-22 |
AUROBINDO PHARMA/ LUPIN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,064 | 1,268 | 83.9% | |
Low | Rs | 584 | 679 | 86.1% | |
Sales per share (Unadj.) | Rs | 400.3 | 361.0 | 110.9% | |
Earnings per share (Unadj.) | Rs | 45.7 | -33.2 | -137.6% | |
Cash flow per share (Unadj.) | Rs | 64.9 | 3.3 | 1,980.8% | |
Dividends per share (Unadj.) | Rs | 9.00 | 4.00 | 225.0% | |
Avg Dividend yield | % | 1.1 | 0.4 | 265.7% | |
Book value per share (Unadj.) | Rs | 419.4 | 263.9 | 159.0% | |
Shares outstanding (eoy) | m | 585.94 | 454.48 | 128.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.1 | 2.7 | 76.4% | |
Avg P/E ratio | x | 18.0 | -29.3 | -61.5% | |
P/CF ratio (eoy) | x | 12.7 | 296.8 | 4.3% | |
Price / Book Value ratio | x | 2.0 | 3.7 | 53.3% | |
Dividend payout | % | 19.7 | -12.0 | -163.5% | |
Avg Mkt Cap | Rs m | 482,799 | 442,238 | 109.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 34,509 | 29,893 | 115.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 234,555 | 164,055 | 143.0% | |
Other income | Rs m | 3,226 | 2,137 | 151.0% | |
Total revenues | Rs m | 237,781 | 166,192 | 143.1% | |
Gross profit | Rs m | 42,566 | 2,152 | 1,977.6% | |
Depreciation | Rs m | 11,265 | 16,587 | 67.9% | |
Interest | Rs m | 486 | 1,428 | 34.1% | |
Profit before tax | Rs m | 34,040 | -13,726 | -248.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 7,256 | 1,372 | 529.1% | |
Profit after tax | Rs m | 26,784 | -15,097 | -177.4% | |
Gross profit margin | % | 18.1 | 1.3 | 1,383.2% | |
Effective tax rate | % | 21.3 | -10.0 | -213.3% | |
Net profit margin | % | 11.4 | -9.2 | -124.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 181,227 | 124,577 | 145.5% | |
Current liabilities | Rs m | 81,560 | 82,764 | 98.5% | |
Net working cap to sales | % | 42.5 | 25.5 | 166.7% | |
Current ratio | x | 2.2 | 1.5 | 147.6% | |
Inventory Days | Days | 25 | 33 | 75.7% | |
Debtors Days | Days | 62 | 95 | 65.8% | |
Net fixed assets | Rs m | 155,104 | 91,938 | 168.7% | |
Share capital | Rs m | 586 | 909 | 64.5% | |
"Free" reserves | Rs m | 245,174 | 119,006 | 206.0% | |
Net worth | Rs m | 245,760 | 119,915 | 204.9% | |
Long term debt | Rs m | 2,492 | 1,419 | 175.7% | |
Total assets | Rs m | 336,331 | 216,515 | 155.3% | |
Interest coverage | x | 71.0 | -8.6 | -824.1% | |
Debt to equity ratio | x | 0 | 0 | 85.7% | |
Sales to assets ratio | x | 0.7 | 0.8 | 92.0% | |
Return on assets | % | 8.1 | -6.3 | -128.4% | |
Return on equity | % | 10.9 | -12.6 | -86.6% | |
Return on capital | % | 13.9 | -10.1 | -137.2% | |
Exports to sales | % | 31.1 | 0 | - | |
Imports to sales | % | 11.9 | 0 | - | |
Exports (fob) | Rs m | 72,862 | NA | - | |
Imports (cif) | Rs m | 27,965 | NA | - | |
Fx inflow | Rs m | 77,245 | 53,594 | 144.1% | |
Fx outflow | Rs m | 31,524 | 38,143 | 82.6% | |
Net fx | Rs m | 45,721 | 15,451 | 295.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 50,165 | 3,673 | 1,365.7% | |
From Investments | Rs m | -32,116 | 12,922 | -248.5% | |
From Financial Activity | Rs m | -29,693 | -15,723 | 188.8% | |
Net Cashflow | Rs m | -11,674 | 872 | -1,338.5% |
Indian Promoters | % | 48.8 | 46.8 | 104.1% | |
Foreign collaborators | % | 3.1 | 0.3 | 1,096.4% | |
Indian inst/Mut Fund | % | 38.0 | 41.5 | 91.7% | |
FIIs | % | 20.7 | 14.3 | 145.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 52.9 | 91.1% | |
Shareholders | 359,684 | 382,828 | 94.0% | ||
Pledged promoter(s) holding | % | 15.9 | 0.0 | - |
Compare AUROBINDO PHARMA With: SUN PHARMA DR. REDDYS LAB CIPLA ZYDUS LIFESCIENCES PIRAMAL ENTERPRISES
After opening the day on a flat note, Indian share markets turned volatile during the afternoon session and fell hard as selling was seen in banking and auto stocks.